PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 01/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends PHXM vs. ITRM, VYNE, ESLA, BRNS, RAPT, NRXP, ATNM, CASI, TPST, and SCYXShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Iterum Therapeutics (ITRM), VYNE Therapeutics (VYNE), Estrella Immunopharma (ESLA), Barinthus Biotherapeutics (BRNS), RAPT Therapeutics (RAPT), NRx Pharmaceuticals (NRXP), Actinium Pharmaceuticals (ATNM), CASI Pharmaceuticals (CASI), Tempest Therapeutics (TPST), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Iterum Therapeutics VYNE Therapeutics Estrella Immunopharma Barinthus Biotherapeutics RAPT Therapeutics NRx Pharmaceuticals Actinium Pharmaceuticals CASI Pharmaceuticals Tempest Therapeutics SCYNEXIS Iterum Therapeutics (NASDAQ:ITRM) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Is ITRM or PHXM more profitable? Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -160.85% PHAXIAM Therapeutics N/A N/A N/A Do analysts rate ITRM or PHXM? Iterum Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 218.47%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in ITRM or PHXM? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, ITRM or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Iterum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$38.37M-$2.00-0.79PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media refer more to ITRM or PHXM? In the previous week, Iterum Therapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Iterum Therapeutics and 0 mentions for PHAXIAM Therapeutics. Iterum Therapeutics' average media sentiment score of 1.43 beat PHAXIAM Therapeutics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive PHAXIAM Therapeutics Neutral Does the MarketBeat Community prefer ITRM or PHXM? Iterum Therapeutics received 141 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% PHAXIAM TherapeuticsN/AN/A Which has more risk and volatility, ITRM or PHXM? Iterum Therapeutics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. SummaryIterum Therapeutics beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$178.34M$5.61B$9.14BDividend YieldN/A3.64%5.36%3.98%P/E RatioN/A138.2789.6917.66Price / Sales0.3218,255.241,217.4681.09Price / CashN/A13.0144.3437.71Price / Book0.398.975.134.73Net Income-$240,000.00-$20.89M$118.85M$225.42M7 Day PerformanceN/A7.72%1.40%0.75%1 Month PerformanceN/A9.96%7.53%3.61%1 Year Performance-26.37%108.35%26.68%21.42% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ITRMIterum Therapeutics2.1885 of 5 stars$1.54+3.0%$5.00+225.7%-0.6%$41.69MN/A-0.7610Short Interest ↓Positive NewsVYNEVYNE Therapeutics3.1875 of 5 stars$2.81+2.0%$6.88+145.1%+31.8%$41.37M$420,000.00-3.2630Short Interest ↑ESLAEstrella Immunopharma0.4955 of 5 stars$1.13-3.4%N/A-0.9%$40.88MN/A-4.35N/AShort Interest ↓Gap DownBRNSBarinthus Biotherapeutics2.7211 of 5 stars$1.01+0.7%$5.17+412.6%-63.1%$40.55M$800,000.00-0.68107Short Interest ↑RAPTRAPT Therapeutics4.7626 of 5 stars$1.17+0.4%$9.56+720.2%-95.5%$40.38M$1.53M-0.4280Short Interest ↓Gap UpNRXPNRx Pharmaceuticals3.0732 of 5 stars$3.31+16.0%$31.67+858.1%-92.0%$39.90MN/A-1.542Analyst ForecastShort Interest ↑ATNMActinium Pharmaceuticals1.6096 of 5 stars$1.28-1.2%$7.40+480.4%N/A$39.78M$80,000.00-0.9230CASICASI Pharmaceuticals4.5459 of 5 stars$2.55-0.2%$6.00+135.7%-62.2%$39.58M$33.88M-1.15180Analyst ForecastShort Interest ↓Positive NewsGap DownTPSTTempest Therapeutics2.4141 of 5 stars$0.91-3.7%$20.00+2,109.9%-74.5%$39.49MN/A-0.5920Short Interest ↓SCYXSCYNEXIS0.9559 of 5 stars$1.03+0.5%N/A-43.7%$38.90M$140.14M-1.3960Positive News Related Companies and Tools Related Companies Iterum Therapeutics Competitors VYNE Therapeutics Competitors Estrella Immunopharma Competitors Barinthus Biotherapeutics Competitors RAPT Therapeutics Competitors NRx Pharmaceuticals Competitors Actinium Pharmaceuticals Competitors CASI Pharmaceuticals Competitors Tempest Therapeutics Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHXM) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts